SCHEMBL2907126

SCHEMBL2907126

Cc1ccc(S(=O)(=O)N2CCc3cc(OCCCN4CCCC4)sc3C2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 11/20 0.53
▸ ESR1 P03372 1/20 0.43
▸ ESR2 Q92731 1/20 0.43
▸ POLB P06746 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MBTD1 Q05BQ5 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CD4 P01730 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907958 0.99 HRH3 (0.55) HRH3ESR1ESR2POLBALDH1A1
SCHEMBL1422860 0.92 HRH3 (0.53) HRH3ESR1ESR2POLBALDH1A1
SCHEMBL1423041 0.91 HRH3 (0.55) HRH3ESR1ESR2POLBALDH1A1
SCHEMBL2909750 0.90 HRH3 (0.52) HRH3ESR1ESR2ALDH1A1TSHR
SCHEMBL2906731 0.90 HRH3 (0.66) HRH3ESR1ESR2ALDH1A1MEN1
SCHEMBL2910178 0.90 HRH3 (0.51) HRH3ALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2914096 0.90 HRH3 (0.53) HRH3TSHRRECQLL3MBTL1
SCHEMBL2913129 0.90 HRH3 (0.51) HRH3POLBALDH1A1GAATSHR
SCHEMBL2913116 0.90 HRH3 (0.53) HRH3ALDH1A1TSHRL3MBTL1MEN1
SCHEMBL2913820 0.89 HRH3 (0.67) HRH3ESR1ESR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2102215-B1 4,5,6,7-TETRAHYDRO-THIENO [2,3-C]PYRIDINES AS H3 MODULATORS HOFFMANN LA ROCHE (CH) 2010-09-01 — — EP claimed
US-20080146559-A1 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 — — US claimed
EP-2102215-B1 4,5,6,7-TETRAHYDRO-THIENO [2,3-C]PYRIDINES AS H3 MODULATORS HOFFMANN LA ROCHE (CH) 2010-09-01 — — EP disclosed
US-20080146559-A1 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146559-A1 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives HRH4, HRH3, HRH2 HRH3 2/4885ESR1 581/4885ESR2 474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback